Acura Pharmaceuticals Financial Statements
Acura Pharmaceuticals Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
This data is provided as per license from EDGAR Online
Acura Pharmaceuticals Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 6.4 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (4.9) | (10.8) | (11.6) |
| Total Net Income ($ mil.) | (4.3) | (6.0) | (12.1) |
| Diluted EPS (Net Income) | (0.11) | (0.80) | (1.80) |
Acura Pharmaceuticals Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 17.21 | 3.77 | 1.54 |
| Price/Earnings Ratio | 27.03 | 15.99 | 15.14 |
| Price/Book Ratio | 15.37 | 2.70 | 1.46 |
| Price/Cash Flow Ratio | 21.44 | 11.60 | 9.41 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Acura Pharmaceuticals Financial Ratios
Acura Pharmaceuticals Competitive Intelligence
| Elite Pharmaceuticals | Endo Pharmaceuticals | Pain Therapeutics | |
|---|---|---|---|
| Annual Sales ($ mil.) | 1.1 | 1,085.6 | 66.0 |
| Employees | -- | 1,208 | -- |
| Market Cap ($ mil.) | 13.6 | 3,253.3 | 309.4 |
Competitive Landscape
